“What We Know About Stroke Is That” ‘time is brain’† Previously we had few effective therapies for stroke, but in recent years we have developed extremely robust and successful therapies, as long as we can diagnose and treat the problem at a very early stage. That’s why this project is so exciting,” says neurosurgeon William Gormley, MD, MPH, MBA. “Expanding access by establishing mobile CT-Perfusion scanners that could potentially be deployed in existing ambulances and directly reach affected patients where they are first seen changes everything. The rapid screening, early detection and diagnosis of cerebral palsy Ischemia means we will be able to reverse strokes, save more brains and prevent major morbidity and mortality from this devastating disease.”
Indeed, the combined tens of thousands of ambulances, urgent care centers and homes for the elderly in the United States only could benefit from an affordable point-of-care CT-P device. By deploying this future device in urban and rural areas, many more individuals suffering from acute stroke can be rapidly evaluated and treated within the favorable window, reducing disability and improving functional independence and quality of life for affected individuals. is improved.
Complementary to this project is a patent Xoran recently received for a modular computed tomography (CT) system assembly. “This revolutionary cone beam CT configuration combined with our more than twenty current patents unlocks a plethora of new possibilities. The technology is just the start of a new generation of Xoran’s point-of-care (POC) imaging devices,” explains Misha Rakici, Xoran CEO. “In the future, these advances mean that ultra-compact CT can fit into existing ambulances without the need for a dedicated mobile stroke unit for early stroke detection. It can also be used by first responders in frontline and natural disaster scenarios such as by military personnel on the battlefield. The possibilities for highly deployable head CT are virtually limitless.”
About 795,000 people suffer strokes every year in the US alone. When a person is suffering from an acute stroke, time is of the essence; however, it is critical to assess the type of stroke as well as the amount and location of potentially recoverable brain tissue to determine the appropriate treatment route and priority to achieve the best outcome for that individual.
About Xoran Technologies
Since 2001, Xoran has been the pioneer and market leader in medical point-of-care cone beam CT systems. Last year, Xoran celebrated its 20th anniversary, an important milestone within the ENT and allergy community. Xoran’s flagship product, MiniCAT, a low-dose upright CBCT solution, is an essential tool for ENT clinicians to identify and diagnose sinus and ear conditions right where the clinician sees the patient. Today, more than 1,000 Xoran CT systems are installed worldwide.
Xoran is located in Ann Arbor, Michigan† For more information visit www.xorantech.com
© 2022 Xoran Technologies, LLC
SOURCE Xoran Technologies, LLC